Concepedia

Hilary Calvert

HC

Statistics

Publications

50

Citations

5.8K

H-Index

32

Active since

1993

Affiliations

Newcastle University(Current)

Royal Marsden Hospital

University College London

North Tyneside General Hospital

Beatson West of Scotland Cancer Centre

Hilary Calvert is an author at Newcastle University specializing in medicine, oncology, and pharmacology.

Publications per year

1993–2019

50

Publications

50

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 831 citations

, , +16

Temozolomide and treatment of malignant glioma.

Henry S. Friedman, Tracy Kerby, Hilary Calvert · PubMed · 2000 · 725 citations

, , +16

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ruth Plummer, Christopher J. Jones, Mark R. Middleton et al. · Clinical Cancer Research · 2008 · 384 citations · Full text

, , +15

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours

Ruth Plummer, Richard H. Wilson, Hilary Calvert et al. · British Journal of Cancer · 2011 · 381 citations · Full text

, , +17

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Timothy A. Yap, Laura Vidal, Jan Adam et al. · Journal of Clinical Oncology · 2010 · 344 citations · Full text

, , +16

1–5 of 50